Effect of Intensive Blood Pressure Control With Valsartan on Urinary Albumin Excretion in Normotensive Patients With Type 2 Diabetes

American Journal of Hypertension

Volumn 19, Issue 12, 2006, Pages 1241-1248

  Estacio, Raymond O ^a   Coll, Joseph R ^a   Tran, Zung Vu ^a   Schrier, Robert W ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

Blood pressure; diabetic nephropathy; valsartan

Indexed keywords

ALBUMIN; CREATININE; HEMOGLOBIN A1C; PLACEBO; VALSARTAN;

ADULT; AGED; ARTICLE; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETIC NEPHROPATHY; DIASTOLIC BLOOD PRESSURE; DISEASE DURATION; DRUG DOSE TITRATION; DRUG EFFECT; ETHNOLOGY; FEMALE; FOLLOW UP; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; URINARY EXCRETION;

ADULT; AGED; AGED, 80 AND OVER; ALBUMINURIA; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; COLORADO; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DIABETIC NEUROPATHIES; DIABETIC RETINOPATHY; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; KIDNEY FUNCTION TESTS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TETRAZOLES; TIME FACTORS; TREATMENT OUTCOME; VALINE;

EID: 33845215520     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjhyper.2006.05.011     Document Type: Article

References (29)

1. Collins A.J., Kasiske B., Herzog C., Chen S.C., Everson S., Constantini E., Grimm R., McBean M., Xue J., Chavers B., Matas A., Manning W., Louis T., Pan W., Liu J., Li S., Roberts T., Dalleska F., Snyder J., Ebben J., Frazier E., Sheets D., Johnson R., Li S., Dunning S., Berrini D., Guo H., Solid C., Arko C., Daniels F., Wang X., Forrest B., Gilbertson D., St Peter W., Frederick P., Eggers P., and Agodoa L. Excerpts from the United States Renal Data System 2003 Annual Data Report: atlas of end-stage renal disease in the United States. Am J Kidney Dis 42 6 Suppl 5 (2003) A5-A7
2. Hogan P., Dall T., and Nikolov P. Economic Costs of Diabetes in the U.S. in 2002. Diabetes Care 26 (2003) 917-932
3. Mogensen C.E. Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N Engl J Med 310 (1984) 356-360
4. Mattock M.B., Morrish N.J., Viberti G., Keen H., Fitzgerald A.P., and Jackson G. Prospective study of microalbuminuria as predictor of mortality in NIDDM. Diabetes 41 (1992) 736-741
5. Borch-Johnsen K., and Kreiner S. Proteinuria: value as predictor of cardiovascular mortality in insulin dependent diabetes mellitus. Br Med J Clin Res Ed 294 (1987) 1651-1654
6. Miettinen H., Haffner S.M., Lehto S., Ronnemaa T., Pyorala K., and Laakso M. Proteinuria predicts stroke and other atherosclerotic vascular disease events in nondiabetic and non-insulin-dependent diabetic subjects. Stroke 27 (1996) 2033-2039
7. Hockensmith M.L., Estacio R.O., Mehler P., Havranek E.P., Ecder S.T., Lundgren R.A., and Schrier R.W. Albuminuria as a predictor of heart failure hospitalizations in patients with type 2 diabetes. J Card Fail 10 (2004) 126-131
8. De Zeeuw D., Remuzzi G., Parving H.H., Keane W.F., Zhang Z., Shahinfar S., Snapinn S., Cooper M.E., Mitch W.E., and Brenner B.M. Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation 110 (2004) 921-927
9. Parving H.H., Andersen A.R., Smidt U.M., Hommel E., Mathiesen E.R., and Svendsen P.A. Effect of antihypertensive treatment on kidney function in diabetic nephropathy. Br Med J (Clin Res Ed) 294 (1987) 1443-1447
10. Schrier R.W., Estacio R.O., Esler A., and Mehler P. Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int 61 (2002) 1086-1097
11. Lewis E.J., Hunsicker L.G., Bain R.P., and Rohde R.D. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 329 (1993) 1456-1462
12. Lewis E.J., Hunsicker L.G., Clarke W.R., Berl T., Pohl M.A., Lewis J.B., Ritz E., Atkins R.C., Rohde R., and Raz I. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345 (2001) 851-860
13. Brenner B.M., Cooper M.E., De Zeeuw D., Keane W.F., Mitch W.E., Parving H.H., Remuzzi G., Snapinn S.M., Zhang Z., and Shahinfar S. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345 (2001) 861-869
14. Chobanian A.V., Bakris G.L., Black H.R., Cushman W.C., Green L.A., Izzo Jr. J.L., Jones D.W., Materson B.J., Oparil S., Wright Jr. J.T., and Roccella E.J. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. J Am Med Assoc 289 (2003) 2560-2572
15. Arauz-Pacheco C., Parrott M.A., and Raskin P. Hypertension management in adults with diabetes. Diabetes Care 27 (2004) 65S-667
16. Bretzel R.G. Effects of antihypertensive drugs on renal function in patients with diabetic nephropathy. Am J Hypertens 10 (1997) 208S-217S
17. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. Br Med J 317 (1998) 703-713
18. Ravid M., Savin H., Jutrin I., Bental T., Katz, Bernard, and Lishner M. Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. Ann Intern Med 118 (1993) 577-581
19. Parving H.H., Lehnert H., Brochner-Mortensen J., Gomis R., Andersen S., and Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 345 (2001) 870-878
20. Barnett A.H., Bain S.C., Bouter P., Karlberg B., Madsbad S., Jervell J., and Mustonen J. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med 351 (2004) 1952-1961
21. Ahmad J., Siddiqui M.A., and Ahmad H. Effective postponement of diabetic nephropathy with enalapril in normotensive type 2 diabetic patients with microalbuminuria. Diabetes Care 20 (1997) 1576-1581
22. Sano T., Kawamura T., Matsumae H., Sasaki H., Nakayama M., Hara T., Matsuo S., Hotta N., and Sakamoto N. Effects of long-term enalapril treatment on persistent micro-albuminuria in well-controlled hypertensive and normotensive NIDDM patients. Diabetes Care 17 (1994) 420-424
23. Ruggenenti P., Fassi A., Ilieva A.P., Bruno S., Iliev I.P., Brusegan V., Rubis N., Gherardi G., Arnoldi F., Ganeva M., Ene-Iordache B., Gaspari F., Perna A., Bossi A., Trevisan R., Dodesini A.R., and Remuzzi G. Preventing microalbuminuria in type 2 diabetes. N Engl J Med 351 (2004) 1941-1951
24. Estacio R.O., Jeffers B.W., Hiatt W.R., Biggerstaff S.L., Gifford N., and Schrier R.W. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med 338 (1998) 645-652
25. Pahor M., Psaty B.M., Alderman M.H., Applegate W.B., Williamson J.D., and Furberg C.D. Therapeutic benefits of ACE inhibitors and other antihypertensive drugs in patients with type 2 diabetes. Diabetes Care 23 (2000) 888-892
26. Jones S.C., Bowes P.D., Hall E., Connolly V., Kelly W.F., and Bilous R.W. HOPE for patients with type 2 diabetes: an application of the findings of the MICRO-HOPE substudy in a British hospital diabetes clinic. Diabet Med 18 (2001) 667-670
27. Lindholm L.H., Dahlof B., Edelman J.M., Ibsen H., Borch-Johnsen K., Olsen M.H., Snapinn S., and Wachtell K. Effect of losartan on sudden cardiac death in people with diabetes: data from the LIFE study 8. Lancet 362 (2003) 619-620
28. Ravid M., Brosh D., Levi Z., Bar-Dayan Y., Ravid D., and Rachmani R. Use of enalapril to attenuate decline in renal function in normotensive, normoalbuminuric patients with type 2 diabetes mellitus. A randomized, controlled trial. Ann Intern Med 128 (1998) 982-988
29. Gerstein H.C., Mann J.F., Yi Q., Zinman B., Dinneen S.F., Hoogwerf B., Halle J.P., Young J., Rashkow A., Joyce C., Nawaz S., and Yusuf S. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. J Am Med Assoc 286 (2001) 421-426